TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Judge blocks Edwards’ JenaValve acquisition—FTC calls it a ‘major win’ for Trump administration
The FTC argued that the $945M deal, first announced in 2024, was "anticompetitive." A federal judge agreed.
TAVR, other interventional procedures may provide value for patients with carcinoid heart disease
These patients are typically treated with surgery, but those procedures carry their own risks that clinicians would prefer to avoid.
Cardiologists perform first procedure of its kind to prevent coronary obstruction after TAVR
A vulnerable heart patient required TAVR, but he faced an extremely high risk of coronary obstruction. Leaflet modification and snorkel stenting were not possible, so the group turned to a brand new treatment option: the VECTOR procedure.
TAVR remains a viable treatment strategy for cancer patients
Improvements in care have resulted in a growing number of patients who go on to be diagnosed with both cancer and severe aortic stenosis. TAVR appears to be an effective treatment option for those individuals, and it may help them go on to receive life-saving cancer therapies.
TAVR or SAVR? Market competition may be influencing these decisions
Hospitals located in more competitive markets may be more likely to perform TAVR instead of SAVR, according to a new analysis of more than 130,000 patients. Is this a reason for concern?

court judge gavel business man bankruptcy lawsuit

Judge blocks Edwards’ JenaValve acquisition—FTC calls it a ‘major win’ for Trump administration

The FTC argued that the $945M deal, first announced in 2024, was "anticompetitive." A federal judge agreed.

TAVR, other interventional procedures may provide value for patients with carcinoid heart disease

These patients are typically treated with surgery, but those procedures carry their own risks that clinicians would prefer to avoid.

Newsweek ranked the 50 best heart hospitals in the world

Cardiologists perform first procedure of its kind to prevent coronary obstruction after TAVR

A vulnerable heart patient required TAVR, but he faced an extremely high risk of coronary obstruction. Leaflet modification and snorkel stenting were not possible, so the group turned to a brand new treatment option: the VECTOR procedure.

TAVR remains a viable treatment strategy for cancer patients

Improvements in care have resulted in a growing number of patients who go on to be diagnosed with both cancer and severe aortic stenosis. TAVR appears to be an effective treatment option for those individuals, and it may help them go on to receive life-saving cancer therapies.

business marketing meal lunch food group project team building

TAVR or SAVR? Market competition may be influencing these decisions

Hospitals located in more competitive markets may be more likely to perform TAVR instead of SAVR, according to a new analysis of more than 130,000 patients. Is this a reason for concern?

cardiologists going through the certification process

CMS considers Medicare coverage for TAVR in asymptomatic patients

After an official request from Edwards Lifesciences, CMS is rethinking its coverage policy for the use of TAVR to treat asymptomatic severe aortic stenosis. The agency is accepting public comments on this topic until Jan. 14.

Newest TAVR valve from Edwards Lifesciences improves survival, real-world data confirm

A fifth-generation TAVR valve from Edwards Lifesciences was associated with improved outcomes compared to the device's predecessors in a new real-world analysis out of Cedars Sinai.

TAVR still a safe treatment option for immunocompromised patients

While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.